Table 1. Outcomes in patients with functioning adenomas after ablation therapy.
| Author | Year | Type of ablation | Tumor no. | Patient no. | Type of functioning tumor | Tumor size (cm) | Resolution of Biochemical marker | Follow-up | Residual or recurrence | Complication |
|---|---|---|---|---|---|---|---|---|---|---|
| Arima et al7 | 2007 | RFA | 4 | 4 | Cortisol-secreting adenoma | 2.7 ± 0.6 (2.0–3.5) | All patients (100%) | 33 mo (20–46 mo) | 25% (¼) after first ablation, 0% after second ablation | Pneumothorax (n = 1) |
| Xiao et al9 | 2008 | PAI, PEI | 15 | 12 | Aldosteronoma (n = 11), cortisol-secreting adenoma (n = 6) | 2.8 ± 0.7 (2.1–4.4) | All patients (100%) | 2 y | 0% | No |
| Mendiratta-Lala et al5 | 2010 | RFA | 13 | 13 | Aldosteronoma (n = 10), cortisol-secreting adenoma (n = 1), testosterone-secreting adenoma (n = 1), pheochromocytoma (n = 1) | < 3.2 (1.0–3.2) | All patients (100%) | 21.2 mo (6–60 mo) | 0% | Small pneumothorax (n = 1) Limited hemothorax (n = 1) Self-limited procedural hypertension (n = 2) |
| Liu et al6 | 2010 | RFA | 24 | 24 | Aldosteronoma | 1.6 (0.4–2.5) | 23 of 24 patients (95.8%) | 21.2 mo (6.1–38.5 mo) | 0% | Small pneumothorax (n = 1) Retroperitoneal hematoma (n = 3) |
Abbreviations: mo, months; PAI, percutaneous acetic acid injection; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation.